Global Phosphodiesterase (PDE) Inhibitors Market – Industry Trends and Forecast to 2029

Global Phosphodiesterase (PDE) Inhibitors Market Analysis and Size

The global phosphodiesterase (PDE) inhibitors market is expected to witness significant growth during the forecast period. Rising prevalence of cardiovascular diseases worldwide and emerging markets are the factors responsible for the growth of this market. The growing preference for PDE5 inhibitors with respect to the other types, to treat erectile dysfunction and pulmonary hypertension is also boosting the industry growth. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global phosphodiesterase (PDE) inhibitors market in the forecast period 2022-2029. The expected CAGR of global phosphodiesterase (PDE)  inhibitors market is tend to be around 6.0% in the mentioned forecast period. The market was valued at USD 2.9 billion in 2021, and it would grow upto USD 4.62 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

PDE, also referred to as phosphodiesterase’s, are a diverse class of enzyme hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. PDE inhibitors are the class of drugs that inhibit the phosphodiesterase’s enzymes. These inhibitors break off the phosphate groups and decrease cAMP or cGMP in target cells. It is becoming of great importance to the healthcare sector and is expected to expand in the coming times.

Global Phosphodiesterase (PDE) Inhibitors Market Scope and Segmentation

Global Phosphodiesterase (PDE) Inhibitors Market Dynamics

Drivers

• Increased Incidence of Erectile Dysfunction

Increasing prevalence of erectile dysfunction are expected to boost the market growth over the forecast period 2022-2029. For instance, according to the World Health Organization (WHO) reports, approximately 150 million people are affected by erectile dysfunction globally, and the number is expected to reach 230 million by 2025. Erectile Dysfunction is a common medical condition affecting about 15% of men annually. Thus, it boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Strategic Collaborations and Acquisitions

Many increased collaborations regarding the glycopeptide antibiotics are boosting the market growth. For instance, Adamis Pharmaceuticals Corporation announced that it has been performing pre-IND development for tadalafil to treat patients with erectile dysfunction. In addition to this, Aspargo Laboratories, Inc. received the international rights to Sildenafil oral spray which is used for the treatment of erectile dysfunction in September 2020.

• Increasing Demand for Retail Pharmacies

The rise in the number of PDE inhibitors delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Risk of Side-Effects

The varied side-effects that are associated with PDE inhibitors could curb the growth of the global PDE inhibitors market over a forecast period. Side-effects such as dyspepsia and headache, and to a lesser extent, myalgia, low-back pain, flushing, and rhinitis are visible with the use of PDE inhibitors.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global phosphodiesterase (PDE) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global phosphodiesterase (PDE) inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Phosphodiesterase (PDE) Inhibitors Market

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

In the post-pandemic era, changes are witnessed in use of different inhibitors. The socioeconomic stressors have also boosted the demand for these drugs. Thus, this will leave a significant impact on the phosphodiesterase (PDE) inhibitors market.

Global Phosphodiesterase (PDE) Inhibitors Market Scope

The global phosphodiesterase (PDE) inhibitors market is segmented on the basis of types, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Specific
• Non-Specific
• Others

Indication

• Congestive Heart Failure
• Erectile Dysfunction
• Inflammatory Airways Disease
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Phosphodiesterase (PDE) Inhibitors Market Regional Analysis/Insights

The global phosphodiesterase (PDE) inhibitors market is analysed and market size insights and trends are provided by types, indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global phosphodiesterase (PDE) inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global phosphodiesterase (PDE) inhibitors market throughout the forecasted period due to due to high prevalence of cardiac surgeries & continuous rise in patients with cardiovascular diseases and rapidly improving health care infrastructure in the region.

North America dominates the market due to large number of patients diagnosed with heart diseases and high R & D and healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Phosphodiesterase (PDE) Inhibitors Market Share Analysis

The global phosphodiesterase (PDE) inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global phosphodiesterase (PDE) inhibitors market

Key players operating in the global phosphodiesterase (PDE) inhibitors market include:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• Abbvie Inc (Ireland)
• Melinta Therapeutics, llc (U.S.)
• Janssen Global Services, LLC (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GlaxoSmithKline plc. (U.K.)
• Bayer AG (Germany)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Lilly (U.S.)
• AstraZeneca (India)

SKU-53778